ReviewPharmaceutical nanotechnology2026
Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.
Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of targeted cancer therapies has become crucial in addressing the limitations of conventional chemotherapy, particularly its lack of specificity and severe side effects. Polymeric nanocarriers have emerged as a transformative solution, providing enhanced drug solubility, selective targeting, and controlled release of therapeutics. This review discusses recent advances in polymeric nanocarriers, emphasizing their capacity to incorporate multiple drugs and optimize delivery through both active and passive targeting strategies, and especially the transition to targeted cancer therapy through the various applied methods in the field. Mechanisms such as the enhanced permeability and retention (EPR) effect for passive targeting, and the use of ligands, peptides, and proteins for active targeting, are explored in depth. Furthermore, the potential of these nanocarriers to improve therapeutic outcomes through targeting specific cellular and subcellular sites, including the nucleus, mitochondria, and endoplasmic reticulum, is examined. These innovations pave the way for the development of safer and more effective cancer treatments with the potential to enhance clinical outcomes.
Indexed as
Identifiers
39917936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.